Catalog No.
Product Name
Application
Product Information
Citations
-
ICMT Inhibitor
ICMT-IN-43 is a potent inhibitor of the isoprenylcysteine carboxyl methyltransferase (ICMT) enzyme, with an IC50 value of 0.04 μM. This compound is instrumental in studying the role of protein methylation in various cellular processes and signaling pathways. ICMT-IN-43 can be utilized in research focused on cancer biology, neurodegenerative diseases, and other pathologies linked to post-translational modifications. -
ICMT Inhibitor
ICMT-IN-39 is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), exhibiting an IC50 of 0.031 μM. This compound effectively disrupts the methylation process of isoprenylated proteins, providing valuable insights into cellular signaling pathways. ICMT-IN-39 is applicable in research focused on the roles of protein modification in various diseases, including cancer and neurodegenerative disorders. -
ICMT Inhibitor
ICMT-IN-32 is a selective inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), showcasing an IC50 value of 0.777 μM. This compound is utilized in biochemical research to examine the role of ICMT in post-translational modifications of proteins. Its inhibitory properties make it valuable for studying signaling pathways and cellular processes related to protein farnesylation. -
ICMT Inhibitor
ICMT-IN-23 is a selective inhibitor of Isoprenylcysteine carboxylmethyltransferase (ICMT), exhibiting an IC50 value of 0.123 μM. This compound plays a crucial role in studying post-translational modifications involved in protein function and stability. ICMT-IN-23 is valuable for research applications focusing on signal transduction, protein interaction studies, and the development of novel therapeutic strategies targeting ICMT. -
ICMT Inhibitor
ICMT-IN-10 is a selective inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT), with an IC50 value of 0.184 μM. This compound effectively disrupts the methylation of isoprenylated proteins, thereby playing a critical role in various signaling pathways. ICMT-IN-10 is valuable for studying the biological implications of ICMT in cancer research and potentially in other diseases associated with aberrant protein methylation. -
ICMT Inhibitor
ICMT-IN-25 is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), with an IC50 value of 0.025 μM. This compound is significant in biochemical research focused on post-translational modifications, particularly in the study of protein localization and function mediated by ICMT. Its application extends to the investigation of cancer biology and other diseases where ICMT plays a crucial role in regulating protein activity. -
ICMT Inhibitor
ICMT-IN-53 is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), exhibiting an IC50 value of 0.96 μM. This compound demonstrates significant antiproliferative activity, effectively inhibiting the growth of MDA-MB-231 and PC3 cancer cell lines with IC50 values of 5.14 μM and 5.88 μM, respectively. ICMT-IN-53's PAMPA permeability makes it suitable for various biological research applications, particularly in the study of cancer cell proliferation and signaling pathways. -
ICMT Inhibitor
ICMT-IN-48 is a competitive inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT), with a Km of 13 μM for the prenylated methyl acceptor, the enzyme's initial substrate. This compound effectively inhibits ICMT activity, demonstrating IC50 values of 3.5 μM at 1×Km S-adenosylmethionine (SAM) and 2.3 μM at 10×Km SAM. ICMT-IN-48 is valuable for studying the role of ICMT in cellular signaling and post-translational regulation related to prenylated proteins in various biological systems. -
ICMT Inhibitor
ICMT-IN-45 is a selective inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), exhibiting an IC50 of 0.132 μM. This compound disrupts the post-translational modification of proteins, thereby influencing signaling pathways associated with cancer and other diseases. ICMT-IN-45 is useful in research applications aimed at understanding ICMT-related biological processes and evaluating the potential therapeutic effects of ICMT inhibition. -
ICMT Inhibitor
ICMT-IN-2 is a potent inhibitor of Isoprenylcysteine carboxyl methyltransferase (ICMT), demonstrating an IC50 value of 0.168 μM. This compound effectively disrupts protein prenylation processes, making it a valuable tool for investigating the role of ICMT in various biological systems. ICMT-IN-2 has applications in studying signal transduction pathways and potential therapeutic interventions in diseases associated with aberrant protein modifications. -
ICMT Inhibitor
ICMT-IN-14 is a selective inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), exhibiting an IC50 value of 0.025 μM. This compound plays a critical role in the modulation of post-translational modifications of proteins associated with oncogenic signaling pathways. ICMT-IN-14 is ideal for research applications focused on protein methylation dynamics and the investigation of cancer biology. -
ICMT Inhibitor
ICMT-IN-47 is a specific inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), with an IC50 value of 0.76 μM. This compound effectively disrupts ICMT activity, which is critical in the post-translational modification of proteins involved in various signaling pathways. ICMT-IN-47 can be utilized in research applications focused on cancer biology, signaling mechanisms, and studies targeting prenylated proteins. -
ICMT Inhibitor
ICMT-IN-19 is a specific inhibitor of Isoprenylcysteine carboxyl methyltransferase (ICMT), demonstrating an IC50 value of 0.026 μM. This compound effectively blocks ICMT activity, impacting post-translational modifications of proteins that can influence various cellular processes. ICMT-IN-19 is suitable for research applications focusing on protein processing, signal transduction, and cancer biology. -
ICMT Inhibitor
ICMT-IN-22 is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), exhibiting an IC50 value of 0.63 μM. This compound is instrumental in research applications related to lipid modification pathways, playing a crucial role in understanding post-translational modifications of proteins. Its use can facilitate studies on cellular signaling, protein stability, and the implications of ICMT activity in various diseases. -
ICMT Inhibitor
ICMT-IN-49 is a potent inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT), demonstrating an IC50 of 0.12 μM. This compound plays a critical role in modulating cellular processes by regulating protein methylation and is valuable in studies targeting protein function and signaling pathways. Research applications include investigations into cancer biology, neurodegenerative diseases, and other conditions where ICMT activity is implicated. -
ICMT Inhibitor
ICMT-IN-42 is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), demonstrating an IC50 value of 0.054 μM. This compound is valuable for research into the role of ICMT in post-translational modifications and protein function regulation. It is suitable for studies investigating cancer biology, signal transduction, and therapeutic development targeting ICMT pathways. -
ICMT Inhibitor
ICMT-IN-9 is an inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), with an IC50 of 0.16 μM. This compound selectively targets ICMT, playing a significant role in regulating post-translational modifications of proteins that are essential for various cellular processes. ICMT-IN-9 can be utilized in research applications focused on cancer biology, signal transduction, and the study of protein interactions influenced by methylation. -
ICMT Inhibitor
ICMT-IN-3 is a potent inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT) with an IC50 value of 0.015 μM. This compound is crucial for studying protein modification processes, particularly in the context of signal transduction and cellular regulation. It serves as a valuable tool for investigating the role of ICMT in various biological pathways and its potential implications in disease mechanisms. -
ICMT Inhibitor
ICMT-IN-4 is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT), with an IC50 value of 0.27 μM. This compound plays a crucial role in the modulation of protein prenylation, impacting various cellular processes. It is valuable for research applications aimed at investigating the role of ICMT in signaling pathways and disease models related to cancer and other disorders. -
ICMT Inhibitor
ICMT-IN-33 is a potent inhibitor of Isoprenylcysteine carboxyl methyltransferase (ICMT) with an IC50 value of 0.46 μM. This compound effectively disrupts the post-translational modification of proteins by inhibiting ICMT activity. It is invaluable for research applications focused on elucidating the role of ICMT in cellular signaling and protein function, as well as potential therapeutic interventions targeting ICMT-related pathways. -
ICMT Inhibitor
Farnesylcysteine (FC) is a competitive inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT). It has been shown to induce an abscisic acid (ABA) hypersensitive phenotype in Arabidopsis thaliana, highlighting its role in plant stress responses. This reagent is valuable for research applications focused on signaling pathways and mechanisms involving ICMT inhibition and ABA-related processes. -
ICMT Inhibitor
ICMT-IN-55 is a selective inhibitor of isoprenylcysteine carboxymethyltransferase (ICMT) with an IC50 of 90 nM. This compound plays a crucial role in inhibiting ICMT activity, leading to the disruption of protein processing involved in various cellular signaling pathways. ICMT-IN-55 is utilized in research focused on understanding the biological significance of protein lipidation and its implications in cancer and other diseases. -
ICMT Inhibitor
Spermatinamine is a natural inhibitor of Isoprenylcysteine carboxyl methyltransferase (ICMT). This novel alkaloid, characterized by its bromotyrosyl-spermine-bromotyrosyl sequence, exhibits significant biological activity affecting protein prenylation. It is derived from the Australian sponge Pseudoceratina and is useful in research applications investigating the roles of ICMT and protein modification pathways in cellular processes. -
ICMT Inhibitor
CAY10677 is a potent inhibitor of Isoprenylcysteine carboxyl methyltransferase (ICMT), a critical enzyme involved in post-translational modifications of proteins. This compound has demonstrated significant ability to inhibit cancer cell proliferation, making it a valuable tool for cancer research. Additionally, CAY10677 exhibits favorable PAMPA permeability, enhancing its applicability in cellular assays. -
ICMT Inhibitor
UCM-13207 is a selective inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT) with potential applications in aging research. This compound has been shown to mitigate progeria-like characteristics and enhance the survival rate in LmnaG609G/G609G mice, serving as an effective tool in studying cellular aging processes and related disorders. Researchers can utilize UCM-13207 to explore therapeutic strategies for age-related diseases. -
ICMT Inhibitor
J1-1 is an inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT), with an IC50 of 1.0 μM. This compound demonstrates notable anticancer activity, making it a valuable tool for research into cancer biology. J1-1 can be utilized in studies focusing on protein modification and its implications in oncogenic signaling pathways. -
LTB4 inhibitor
U-75302 is a potent inhibitor of leukotriene B4, developed as a pyridine analogue. This compound demonstrates significant anti-inflammatory activity, making it valuable for research into various inflammatory diseases. U-75302 can help elucidate the role of leukotriene B4 in pathophysiological processes, contributing to better understanding and potential therapeutic strategies in inflammation-related conditions. -
LTB4 Antagonist
γ-Linolenic acid ethyl ester serves as a leukotriene B4 receptor 4 (LTB4) antagonist. This compound exhibits anti-inflammatory properties by inhibiting LTB4 signaling pathways, which are implicated in various inflammatory conditions. Its applications in research include studying immune responses and exploring therapeutic avenues for inflammation-related diseases. -
BLT1 Antagonist
Moxilubant is a potent BLT1 antagonist, exhibiting a competitive inhibition of LTB4 signaling with an efficacy of 2-4 nM. This compound effectively inhibits LTB4-induced neutrophil activation and functions, making it a valuable tool in the study of inflammatory responses. Research applications include investigations into chronic obstructive pulmonary disease and related conditions characterized by neutrophil-mediated inflammation. -
LTB4 Metabolite
20-Carboxy-Leukotriene B4 is a key metabolite of Leukotriene B4 that targets the BLT1 receptor, demonstrating high affinity binding. This compound effectively inhibits LTB4-mediated neutrophil responses, including migration, degranulation, and leukotriene biosynthesis. It is valuable in research applications focused on inflammation, immune response modulation, and the study of leukotriene signaling pathways. -
Leukotriene D4/E4 Antagonist
Tomelukast is an orally active antagonist of leukotriene D4 and E4, primarily involved in mediating inflammatory responses in asthma. This compound inhibits the action of leukotrienes, thereby reducing bronchoconstriction and inflammatory cell recruitment in the airways. Tomelukast is useful in research applications focused on asthma pathophysiology and the evaluation of anti-inflammatory therapies. -
PGF2α/LTB4 Inhibitor
Darbufelone is a dual inhibitor of prostaglandin F2α (PGF2α) and leukotriene B4 (LTB4) production, primarily targeting the cyclooxygenase enzyme PGHS-2 with an IC50 of 0.19 μM, while showing markedly lower potency against PGHS-1 (IC50 of 20 μM). This compound is valuable for research focused on inflammation, pain modulation, and the role of eicosanoids in various pathological conditions. Its selective inhibition of PGF2α and LTB4 makes Darbufelone a useful tool for studying the intersection of these signaling pathways in cellular responses. -
Unsaturated Fattly Acid
11(Z),14(Z)-Eicosadienoic acid is an unsaturated fatty acid that selectively inhibits [3H] leukotriene B4 (LTB4) binding to pig neutrophil membranes, with a binding affinity characterized by a Ki of 3 μM. This compound exhibits significant anti-inflammatory properties, making it a valuable tool for research focused on inflammatory processes and leukotriene signaling pathways. Its ability to modulate leukotriene interactions supports its use in studies of immune response and related therapeutic areas. -
LTD4/E4 Receptor Antagonist
Ritolukast is a potent antagonist of the LTD4/E4 leukotriene receptors. This compound demonstrates significant biological activity by inhibiting bronchoconstriction induced by aerosolized LTD4, with an ID50 of 0.5 mg/kg in guinea pigs. Ritolukast is primarily utilized in research applications related to respiratory pharmacology and the study of allergic inflammatory responses. -
FPR Inhibitor
Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) acts as an inhibitor of N-formyl peptide receptors (FPR). This compound effectively reduces FMLP-induced release of peptide leukotrienes and disrupts the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids in a three-dimensional fibrin gel model, which simulates the conditions associated with proliferative diabetic retinopathy (PDR) and vascular endothelial growth factor (VEGF). Additionally, Boc-Phe-Leu-Phe-Leu-Phe counteracts the anti-inflammatory and antifibrotic effects of Ac2-26. It is suitable for applications in immunological research. -
CysLT Receptor Antagonist
BAY-u 9773 is a non-selective antagonist of the cysteinyl leukotriene (CysLT) receptors, effectively inhibiting both CysLT1 and CysLT2 with comparable IC50 values. This compound is utilized in research to study leukotriene-mediated processes and to explore therapeutic strategies for conditions associated with cysteinyl leukotrienes, such as asthma and allergic responses. -
CysLT2 Receptor Antagonist
BayCysLT2 is a selective and potent antagonist of the cysteinyl leukotriene 2 (CysLT2) receptor, exhibiting an IC50 value of 53 nM. It effectively inhibits calcium mobilization induced by leukotriene D4 in HEK293 cells expressing human CysLT2 receptors. Additionally, BayCysLT2 demonstrates the ability to reverse LTC4-induced increases in coronary artery perfusion pressure and decreases in contractility in isolated guinea pig hearts, making it valuable for research on cardiovascular and inflammatory responses. -
Leukotriene Receptor Antagonist
KP496 is a selective dual antagonist targeting the Leukotriene D4 receptor and Thromboxane A2 receptor. It exhibits significant inhibition of leukotriene-mediated inflammatory responses, making it valuable in studies of allergic reactions and asthma. This compound is essential for research exploring therapeutic strategies for inflammation-related diseases. -
LTB4 Receptor Antagonist
SB-209247 is a selective leukotriene B4 (LTB4) receptor antagonist, exhibiting high affinity with a Ki of 0.78 nM. This compound effectively inhibits LTB4-induced calcium mobilization, with an IC50 of 6.6 nM, displaying significant anti-inflammatory properties. SB-209247 is valuable for research applications focusing on inflammatory diseases and the modulation of leukotriene signaling pathways. -
LTB4 Inhibitor
Halometasone is a corticosteroid that functions as an inhibitor of leukotriene B4 (LTB4) synthesis. It exhibits anti-inflammatory properties by reducing LTB4 and thymic stromal lymphopoietin (TSLP) levels. Halometasone is widely utilized in research related to psoriasis and other eczematous skin disorders, providing insights into corticosteroid-mediated effects on inflammatory pathways. -
BLT2 Agonist
CAY10583 is a potent and selective full agonist of the Leukotriene B4 receptor type 2 (BLT2). This compound effectively promotes keratinocyte migration in vitro and enhances wound healing in vivo, making it a valuable tool for studies on tissue repair mechanisms. CAY10583 holds potential for therapeutic applications in the treatment of diabetic wounds and related conditions. -
HAMI 3379 Racemate
(Rac)-HAMI 3379 is a racemic mixture of HAMI 3379, a potent and selective antagonist of the Cysteinyl leukotriene 2 (CysLT2) receptor. This compound exhibits significant biological activity in modulating inflammatory processes linked to allergic responses and asthma. It is valuable for research applications focused on understanding the role of leukotrienes in various pathological conditions. -
LTD4/LTE4 Antagonist
SR2640 hydrochloride is a potent and selective competitive antagonist of leukotriene D4 and leukotriene E4. This compound is invaluable for studying the role of leukotrienes in asthma and may provide insights into inflammatory pathways associated with respiratory diseases. Its well-defined mechanism makes it a useful tool for pharmacological research and the development of therapeutic strategies targeting leukotriene-mediated responses. -
Leukotriene Receptor Antagonist
ONO4057 is a potent leukotriene B4 receptor antagonist, exhibiting an IC50 of 0.7±0.3 μM. This compound effectively inhibits the activity of leukotriene B4, which plays a crucial role in inflammatory processes. ONO4057 is utilized in research applications focused on inflammation, asthma, and allergy studies, making it valuable for exploring therapeutic strategies in these areas. -
Leukotriene Receptor Antagonist
REV 5901 is a competitive, orally active antagonist of leukotriene receptors, exhibiting a Ki value of 0.7 μM. In addition to its receptor antagonism, REV 5901 also acts as a 5-lipoxygenase inhibitor. This compound is primarily utilized in research related to asthma, where leukotriene release plays a critical role, and has potential applications in the study of colon carcinoma. -
leukotriene Receptor Antagonist
FPL-55712 free base is a leukotriene receptor antagonist that effectively inhibits bronchoconstriction induced by leukotrienes. Additionally, it antagonizes slow reacting substance of anaphylaxis (SRS-A), making it valuable for research focused on respiratory conditions and allergic responses. This compound is instrumental in studies exploring the modulation of leukotriene pathways in inflammatory diseases. -
Leukotriene Synthesis Inhibitor
L-674573 is a quinoline compound that functions as a selective inhibitor of leukotriene synthesis. It effectively inhibits leukotriene production induced by Calcimycin and N-Formyl-Met-Leu-Phe, with IC50 values of 100 nM and 50 nM, respectively. L-674573 specifically targets and inhibits the translocation of 5-lipoxygenase, making it a valuable tool for research into inflammatory processes and leukotriene-related diseases. Its application is particularly relevant in studies aimed at understanding leukotriene signaling pathways and developing anti-inflammatory therapeutics. -
CysLT1 Receptor Antagonist
Pobilukast is a classical antagonist of the CysLT1 receptor, modulating leukotriene-mediated signaling pathways. It demonstrates significant efficacy in inhibiting bronchoconstriction and inflammation associated with asthma. This compound is primarily utilized in research investigating asthma pathophysiology and potential therapeutic interventions targeting leukotriene receptors. -
CysLT1-2R Antagonist
Quininib is a cysteinyl leukotriene 1 and 2 receptor antagonist, exhibiting IC50 values of 1.2 μM for CysLT1R and 52 μM for CysLT2R. This compound effectively inhibits developmental angiogenesis in the zebrafish eye model, making it a valuable tool for studying ocular neovascular pathologies. Quininib may serve as a complementary agent to existing anti-VEGF biological therapies in research applications focused on angiogenesis and related conditions. -
leukotriene receptor antagonist
Masilukast is a cysteinyl leukotriene D4 (LTD4) receptor antagonist that is administered orally. This compound exhibits significant potential in mitigating the effects of leukotrienes, thus contributing to the management of asthma and related respiratory conditions. It serves as a valuable tool for research into inflammatory pathways and therapeutic interventions targeting asthma.
